Personalis rises as Medicare extends coverage to lung cancer test

Shares of U.S.-based cancer diagnostics firm Personalis PSNL.O rise 2.3% to $8.01 premarket

 Co says Medicare will now cover its NeXT Personal test for monitoring early-stage non-small cell lung cancer, the most common form of the disease

Says the test tracks tiny bits of circulating tumor DNA (ctDNA) in blood that can indicate the presence of cancer; analyzes hundreds of tumor-specific mutations to guide ongoing care decisions

Move follows Medicare approval for the same test in breast cancer patients, co says

Medicare is the U.S. government health insurance program for people aged 65 and older

Shares rose ~38% in 2025